71 related articles for article (PubMed ID: 2167539)
1. Experience of cytomegalovirus infection in heart-lung transplant recipients.
Smyth RL; Scott JP; Higenbottam TW; Wreghitt TG; Stewart S; Fradet G; Clelland CA; Wallwork J
Transplant Proc; 1990 Aug; 22(4):1820-1. PubMed ID: 2167539
[No Abstract] [Full Text] [Related]
2. Ganciclovir treatment of cytomegalovirus infection in heart-lung and double-lung transplant recipients.
Cerrina J; Bavoux E; Le Roy Ladurie F; Herve P; Lafont D; Simonneau G; Dartevelle P
Transplant Proc; 1991 Feb; 23(1 Pt 2):1174-5. PubMed ID: 1846457
[No Abstract] [Full Text] [Related]
3. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma of donor-positive/recipient-negative serostatus.
Avery RK
Clin Infect Dis; 2007 Aug; 45(4):448-9. PubMed ID: 17638192
[No Abstract] [Full Text] [Related]
5. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
[TBL] [Abstract][Full Text] [Related]
6. [Cytomegalovirus infection in lung transplantation; current status, detection, prophylactic treatment].
Aoe M; Tao H; Yamane M; Toyooka S; Sano Y; Okazaki M; Date H
Kyobu Geka; 2007 Oct; 60(11):988-92. PubMed ID: 17926902
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection and prophylaxis in heart transplantation.
Laske A; Gallino A; Carrel T; Niederhäuser U; von Segesser LK; Turina MI
Transplant Proc; 1993 Feb; 25(1 Pt 2):1427-8. PubMed ID: 8382870
[No Abstract] [Full Text] [Related]
8. Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients.
Kaplan CS; Petersen EA; Icenogle TB; Copeland JG; Villar HV; Sampliner R; Minnich L; Ray CG
Arch Intern Med; 1989 Sep; 149(9):2095-100. PubMed ID: 2549896
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
[TBL] [Abstract][Full Text] [Related]
10. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
11. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
[TBL] [Abstract][Full Text] [Related]
12. Cytomegalovirus colitis in a pediatric heart transplant patient.
Etheridge SP; Bolman RM; Braunlin EA
Clin Transplant; 1994 Aug; 8(4):409-12. PubMed ID: 7949549
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
Thomas LD; Milstone AP; Miller GG; Loyd JE; Stephen Dummer J
Clin Transplant; 2009; 23(4):476-83. PubMed ID: 19453645
[TBL] [Abstract][Full Text] [Related]
14. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
Shah T; Lai WK; Mutimer D
Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
[TBL] [Abstract][Full Text] [Related]
15. Three-year experience with human cytomegalovirus infections in heart transplant recipients.
Grossi P; Revello MG; Minoli L; Percivalle E; Zavattoni M; Poma G; Martinelli L; Gerna G
J Heart Transplant; 1990; 9(6):712-9. PubMed ID: 2177498
[TBL] [Abstract][Full Text] [Related]
16. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
17. Is cytomegalovirus infection going to be a problem among heart transplant recipients in Singapore?
Sivathasan C; Doraisingham S; Ling AE; Ng A; Allen DM; Tong MC
Transplant Proc; 1992 Oct; 24(5):2019-21. PubMed ID: 1329290
[No Abstract] [Full Text] [Related]
18. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
19. Prevention of cytomegalovirus disease.
Bailey TC
Semin Respir Infect; 1993 Sep; 8(3):225-32. PubMed ID: 8016483
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
